Liquidia Corporation (LQDA)
What Next For Liquidia After Launch?
Liquidia shipped its first FDA-approved product, Yutrepia for pulmonary hypertension in June entering market worth several billion dollars. Market sentiment remains skeptical, pricing in limited Yutrepia success despite a large addressable market and competitor United Therapeutics' strong sales. Valuation scenarios suggest substantial upside if LQDA captures meaningful market share, but capital raises and medium-term competition could weigh on expectations.
Liquidia Corporation (LQDA) Q1 2025 Earnings Call Transcript
Liquidia Corporation (NASDAQ:LQDA ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - Chief Executive Officer Michael Kaseta - Chief Operating Officer and Chief Financial Officer Rusty Schundler - General Counsel Rajeev Saggar - Chief Medical Officer Scott Moomaw - Chief Commercial Officer Conference Call Participants Julian Harrison - BTIG, LLC Kambiz Yazdi - Jefferies Group LLC Greg Harrison - Scotiabank Cory Jubinville - LifeSci Capital Serge Belanger - Needham & Company, LLC Ryan Deschner - Raymond James Financial, Inc. Operator Good morning, and welcome everyone to the Liquidia Corporation First Quarter 2025 Financial Results and Corporate Update Conference Call. My name is Ari, and I will be your conference operator today.
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates
Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.54 per share a year ago.
Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month
Liquidia Corporation's legal victory clears the path for Yutrepia's FDA approval and market entry, targeting PAH and PH-ILD, with final approval expected by May 24, 2025. Yutrepia's competitive advantages include a patient-friendly inhaler, lower cost structure, and strong clinical profile, positioning it to capture market share from United Therapeutics' Tyvaso DPI. Liquidia is financially prepared for Yutrepia's launch, boasting $176.5 million in cash and milestone financing, ensuring a smooth commercialization without diluting shareholders.
Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains?
Liquidia Technologies (LQDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Liquidia Corporation (LQDA) Q4 2024 Earnings Call Transcript
Liquidia Corporation (NASDAQ:LQDA ) Q4 2024 Earnings Conference Call March 19, 2025 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - CEO Michael Kaseta - COO and CFO Rajeev Saggar - Chief Medical Officer Scott Moomaw - Chief Commercial Officer Rusty Schundler - General Counsel Conference Call Participants Julian Harrison - BTIG Serge Belanger - Needham Ryan Deschner - Raymond James Greg Harrison - Scotiabank Cory Jubinville - LifeSci Capital Operator Good morning. And welcome everyone to Liquidia Corporation Full Year 2024 Financial Results and Corporate Update Conference Call.
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates
Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.42 per share a year ago.
Liquidia Technologies (LQDA) Moves 5.7% Higher: Will This Strength Last?
Liquidia Technologies (LQDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Liquidia named a top pick for 2025 at Needham
Needham analyst Serge Belanger named Liquidia a top pick for 2025 with a Buy rating and $19 price target. The stock was also the analyst's top pick for 2024, and "disappointed" with a negative 2% performance mostly due to the mid-August setback when the FDA delayed approval by retroactively granting Tyvaso DPI a three year exclusivity dating to 2022, Needham points out. The firm says its "investment thesis is stronger now than a year ago." It has a "clear line of sight" for FDA approval of Yutrepia in both pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease by May 23. Yutrepia will launch into an opportunity that will have grown into a $2B market by mid-2025, on its way to over $3B-$4B by 2030, contends the firm.
Does Liquidia Technologies (LQDA) Have the Potential to Rally 132.54% as Wall Street Analysts Expect?
The mean of analysts' price targets for Liquidia Technologies (LQDA) points to a 132.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 126.13% Upside in Liquidia Technologies (LQDA): Can the Stock Really Move This High?
The consensus price target hints at a 126.1% upside potential for Liquidia Technologies (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Liquidia Corporation: Resilience In The Face Of Formidable Opposition Can Pay Off
Liquidia's Yutrepia, a competitor to United Therapeutics' Tyvaso, faces potential market entry in 2025, with promising clinical data and a competitive therapeutic profile. Despite financial challenges and intense competition, Liquidia's low valuation and upcoming product launches present a compelling investment opportunity. Liquidia's legal battles with United Therapeutics are nearing resolution, potentially clearing the path for Yutrepia's commercial launch by mid-2025.
